Answers are grounded in this paper and cite their sources.
Demonstrates sodium pyruvate lowers ox-LDL and inflammation in diabetic atherosclerosis, indicating potential therapeutic benefits.
This study aimed to investigate the protective effects of sodium pyruvate against diabetic atherosclerosis in rats by reducing oxidative stress, ox-LDL levels, and inflammatory responses. Wistar rats were randomly divided into four groups: normal control (NC), diabetes mellitus (DM), diabetic atherosclerosis (DA), and diabetic atherosclerosis treated with sodium pyruvate (DA + SP). Serum levels of malondialdehyde (MDA), superoxide dismutase (SOD), remnant-like particle cholesterol (RLP-C), ox-LDL, low-density lipoprotein particle (LDL-P), the ox-LDL/LDL-P ratio, high-sensitivity C-reactive protein (hs-CRP), and interleukin-6 (IL-6) were measured. Compared with NC and DM groups, DA rats exhibited increased oxidative stress, lipoprotein abnormalities, and inflammation, evidenced by elevated MDA, RLP-C, ox-LDL, LDL-P, ox-LDL/LDL-P ratio, hs-CRP, and IL-6, along with reduced SOD levels. Sodium pyruvate treatment significantly decreased MDA, ox-LDL, ox-LDL/LDL-P ratio, hs-CRP, and IL-6, while increasing SOD activity compared with the DA group. No significant differences in RLP-C and LDL-P were observed between DA and DA + SP groups. Sodium pyruvate alleviates oxidative stress and inflammation and reduces ox-LDL-related indices, suggesting a protective role in diabetic atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Yusuf et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: